Type I interferon-mediated tumor immunity and its role in immunotherapy

被引：196

作者：

Yu, Renren ^{[1
,2
]}

Zhu, Bo ^{[1
,3
]}

Chen, Degao ^{[1
]}

机构：

[1] Third Mil Med Univ, Inst Canc, Xinqiao Hosp, Chongqing 400037, Peoples R China

[2] Wenzhou Med Univ, Affiliated Hosp 1, Dept Oncol, Wenzhou 325000, Peoples R China

[3] Third Mil Med Univ, Xinqiao Hosp, Chongqing Key Lab Immunotherapy, Chongqing 400037, Peoples R China

来源：

CELLULAR AND MOLECULAR LIFE SCIENCES | 2022年 / 79卷 / 03期

基金：

中国国家自然科学基金;

关键词：

IFN-alpha; IFN-beta; Tumor immunity; cGAS; STING; Radiation therapy; Oncolytic virotherapy; REGULATORY T-CELLS; CYCLIC GMP-AMP; ANTITUMOR IMMUNITY; PD-1; BLOCKADE; STING PATHWAY; IFN; CANCER; DNA; ALPHA; RESPONSES;

D O I：

10.1007/s00018-022-04219-z

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Immune checkpoint blockade (ICB) therapies have achieved remarkable clinical responses in patients with many different types of cancer; however, most patients who receive ICB monotherapy fail to achieve long-term responses, and some tumors become immunotherapy-resistant and even hyperprogressive. Type I interferons (IFNs) have been demonstrated to inhibit tumor growth directly and indirectly by acting upon tumor and immune cells, respectively. Furthermore, accumulating evidence indicates that endo- and exogenously enhancing type I IFNs have a synergistic effect on anti-tumor immunity. Therefore, clinical trials studying new treatment strategies that combine type I IFN inducers with ICB are currently in progress. Here, we review the cellular sources of type I IFNs and their roles in the immune regulation of the tumor microenvironment. In addition, we highlight immunotherapies based on type I IFNs and combination therapy between type I IFN inducers and ICBs.

引用

页数：24

共 166 条

[1] Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP [J].

Ablasser, Andrea ;

Schmid-Burgk, Jonathan L. ;

Hemmerling, Inga ;

Horvath, Gabor L. ;

Schmidt, Tobias ;

Latz, Eicke ;

Hornung, Veit .

NATURE, 2013, 503 (7477) :530-+

[2]

Adamus Tomasz, 2018, Contemp Oncol (Pozn), V22, P56, DOI 10.5114/wo.2018.73887

[3] Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma [J].

Andtbacka, Robert H. I. ;

Kaufman, Howard L. ;

Collichio, Frances ;

Amatruda, Thomas ;

Senzer, Neil ;

Chesney, Jason ;

Delman, Keith A. ;

Spitler, Lynn E. ;

Puzanov, Igor ;

Agarwala, Sanjiv S. ;

Milhem, Mohammed ;

Cranmer, Lee ;

Curti, Brendan ;

Lewis, Karl ;

Ross, Merrick ;

Guthrie, Troy ;

Linette, Gerald P. ;

Daniels, Gregory A. ;

Harrington, Kevin ;

Middleton, Mark R. ;

Miller, Wilson H., Jr. ;

Zager, Jonathan S. ;

Ye, Yining ;

Yao, Bin ;

Li, Ai ;

Doleman, Susan ;

VanderWalde, Ari ;

Gansert, Jennifer ;

Coffin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) :2780-U98

[4] Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma. [J].

Andtbacka, Robert Hans Ingemar ;

Ross, Merrick I. ;

Agarwala, Sanjiv S. ;

Taylor, Matthew H. ;

Vetto, John T. ;

Neves, Rogerio Izar ;

Daud, Adil ;

Khong, Hung T. ;

Ungerleider, Richard S. ;

Tanaka, Maki ;

Grossmann, Kenneth F. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[5] Growing tumors induce a local STING dependent Type I IFN response in dendritic cells [J].

Andzinsk, Lisa ;

Spanier, Julia ;

Kasnitz, Nadine ;

Kroeger, Andrea ;

Jin, Lei ;

Brinkmann, Melanie M. ;

Kalinke, Ulrich ;

Weiss, Siegfried ;

Jablonska, Jadwiga ;

Lienenklaus, Stefan .

INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (06) :1350-1357

[6] Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human [J].

Andzinski, Lisa ;

Kasnitz, Nadine ;

Stahnke, Stephanie ;

Wu, Ching-Fang ;

Gereke, Marcus ;

von Koeckritz-Blickwede, Maren ;

Schilling, Bastian ;

Brandau, Sven ;

Weiss, Siegfried ;

Jablonska, Jadwiga .

INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (08) :1982-1993

[7] Delayed apoptosis of tumor associated neutrophils in the absence of endogenous IFN-β [J].

Andzinski, Lisa ;

Wu, Ching-Fang ;

Lienenklaus, Stefan ;

Kroeger, Andrea ;

Weiss, Siegfried ;

Jablonska, Jadwiga .

INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (03) :572-583

[8] Immunotherapeutic effects of intratumoral nanoplexed poly I:C [J].

Angela Aznar, M. ;

Planelles, Lourdes ;

Perez-Olivares, Mercedes ;

Molina, Carmen ;

Garasa, Saray ;

Etxeberria, Inaki ;

Perez, Guiomar ;

Rodriguez, Inmaculada ;

Bolanos, Elixabet ;

Lopez-Casas, Pedro ;

Rodriguez-Ruiz, Maria E. ;

Perez-Gracia, Jose L. ;

Marquez-Rodas, Ivan ;

Teijeira, Alvaro ;

Quintero, Marisol ;

Melero, Ignacio .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7

[9] Suppression of Intratumoral CCL22 by Type I Interferon Inhibits Migration of Regulatory T Cells and Blocks Cancer Progression [J].

Anz, David ;

Rapp, Moritz ;

Eiber, Stephan ;

Koelzer, Viktor H. ;

Thaler, Raffael ;

Haubner, Sascha ;

Knott, Max ;

Nagel, Sarah ;

Golic, Michaela ;

Wiedemann, Gabriela M. ;

Bauernfeind, Franz ;

Wurzenberger, Cornelia ;

Hornung, Veit ;

Scholz, Christoph ;

Mayr, Doris ;

Rothenfusser, Simon ;

Endres, Stefan ;

Bourquin, Carole .

CANCER RESEARCH, 2015, 75 (21) :4483-4493

[10] Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].

Apetoh, Lionel ;

Ghiringhelli, Francois ;

Tesniere, Antoine ;

Obeid, Michel ;

Ortiz, Carla ;

Criollo, Alfredo ;

Mignot, Gregoire ;

Maiuri, M. Chiara ;

Ullrich, Evelyn ;

Saulnier, Patrick ;

Yang, Huan ;

Amigorena, Sebastian ;

Ryffel, Bernard ;

Barrat, Franck J. ;

Saftig, Paul ;

Levi, Francis ;

Lidereau, Rosette ;

Nogues, Catherine ;

Mira, Jean-Paul ;

Chompret, Agnes ;

Joulin, Virginie ;

Clavel-Chapelon, Francoise ;

Bourhis, Jean ;

Andre, Fabrice ;

Delaloge, Suzette ;

Tursz, Thomas ;

Kroemer, Guido ;

Zitvogel, Laurence .

NATURE MEDICINE, 2007, 13 (09) :1050-1059

← 1 2 3 4 5 6 7 8 9 10 →